Diese Frage hat das “Office of the National Coordinator for Health IT” in einem anschaulichen Video aufgegriffen. Ich finde das Thema dort informativ aufbereitet 😉
Related Posts
Health 2.0 Spring Fling – Interview with founders Indu Subaiya and Matthew Holt
After wrapping up a second day of hearing so many ideas about start-ups in health care, Health 2.0 Spring Fling in Boston left me wanting to start my own company and join all the entrepreneurs that attended. As a small representative sample of the groups of entrepreneurs that form the Health 2.0 space, who better than the chairs of the Health 2.0 organization to interview? Indu Subaiya, Co-Chairman and CEO of Health 2.0: “Is responsible for Health 2.0’s strategic direction and incredible production values. She started her career in health technology assessment at Quorum Consulting and then served as VP of Healthcare at Gerson Lehrman Group, an investment research firm. Before co-founding Health 2.0 she was Entrepreneur-in-Residence at Physic Ventures, where she helped evaluate companies. When she is not running Health 2.0, she applies her producing and directing skills to making film.” Not to mention that she is also an MD who decided to take the entrepreneur path. I bet many of us can relate. Matthew Holt, Co-Chairman of Health 2.0: “Spent the 1990s learning from the best to be a health care futurist at Institute for the Future, and a survey researcher at Harris Interactive. In the early […]
Video: NYTimes – Mobile Devices ‘On Call’
We recently discovered the following video from the New York Times highlighting the benefits (and potential drawbacks) of using mobile devices in hospitals. We want to share this with you because it demonstrates some unique use-case scenarios of mobile…
5 Elements Of A Pharma Company 2.0
In various posts we have been calling for a change within the pharmaceutical industry. Much of that is not new, yet still nothing seems to change on a bigger scale. Sure, the iPad is becoming an essentiell tool in sales, eDetails have emerged, biotech startups are being bought instead of inhouse R&D, but especially with regards to the patent cliff it’s time for a new kind of pharmaceutical copmany and we simply don’t see that happpening. Here are five parts of todays pharma business that need to be deserve attention and that need be disrupted entirely. Sure, there are many regulatory aspects that need to overcome, but a startup called help! in New York is showing how things can run entirely differently. 1. Sales – The other way round We’ve previously written about Pharma’s sales savior. Is it the iPad? Is it the Telerep? Pharma needs a radically new distribution approach and entirely new sales channel. Still, most of its sales goes through reps working closely with doctors. Showing some allegdly nifty and worthwhile graphics and trying to convince the physician of some drug. In times of guidelines and EBM those fancy graphics are not enough anymore. Sales needs to […]